Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nyse  >  Actavis Inc    

SummaryNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector newsTweets 

Watson Pharmaceuticals, Inc. : Watson Confirms Lialda® Patent Challenge

share with twitter share with LinkedIn share with facebook
share via e-mail
0
05/09/2012 | 10:10pm CEST

PARSIPPANY, N.J., May 9, 2012 /PRNewswire/ -- Watson Pharmaceuticals, Inc. (NYSE: WPI) today confirmed that its subsidiary, Watson Laboratories, Inc. - Florida, filed an Abbreviated New Drug Application (ANDA) with the U.S. Food and Drug Administration (FDA) seeking approval to market Mesalamine Delayed-release Tablets, 1.2g. Watson's ANDA product is a generic version of Shire Development LLC's Lialda®.

Shire Development LLC, Shire Pharmaceutical Development Inc., Cosmo Technologies Limited, and Guiliani International Limited filed suit against Watson on May 8, 2012, in the United States District Court for the Southern District of Florida seeking to prevent Watson from commercializing its ANDA product prior to the expiration of U.S. Patent No. 6,773,720. The lawsuit was filed under the provisions of the Hatch-Waxman Act, resulting in a stay of final FDA approval of Watson's ANDA for up to 30 months from the date the plaintiffs received notice of Watson's ANDA filing or until final resolution of the matter before the court, whichever occurs sooner, subject to any other exclusivities.

For the twelve months ending March 31, 2012, Lialda® had total U.S. sales of approximately $390 million according to IMS Health data.

About Watson Pharmaceuticals, Inc.

Watson Pharmaceuticals, Inc. is an integrated global specialty pharmaceutical company. The Company is engaged in the development, manufacturing, marketing and distribution of generic pharmaceuticals and specialized branded pharmaceutical products focused on Urology and Women's Health. The Company is also developing biosimilar products in Women's Health and Oncology. Additionally, Watson distributes generic and branded pharmaceuticals through its Anda, Inc. distribution business. Watson has operations in many of the world's established and growing international markets.

For press release and other company information, visit Watson Pharmaceuticals' Web site at http://www.watson.com.

Forward-Looking Statement
Statements contained in this press release that refer to non-historical facts are forward-looking statements that reflect Watson's current perspective of existing information as of the date of this release. It is important to note that Watson's goals and expectations are not predictions of actual performance. Actual results may differ materially from Watson's current expectations depending upon a number of factors, risks and uncertainties affecting Watson's business. These factors include, among others, the difficulty of predicting the timing or outcome of product development efforts, including FDA and other regulatory agency approvals and actions, if any; the difficulty of predicting the timing and outcome of the pending patent litigation; the impact of competitive products and pricing; the timing and success of product launches; difficulties or delays in manufacturing; the availability and pricing of third party sourced products and materials; successful compliance with FDA and other governmental regulations applicable to Watson and its third party manufacturers' facilities, products and/or businesses; changes in the laws and regulations, including Medicare and Medicaid, affecting among other things, pricing and reimbursement of pharmaceutical products; and such other risks and uncertainties detailed in Watson's periodic public filings with the Securities and Exchange Commission, including but not limited to Watson's Quarterly Report on Form 10-Q for the quarter ended March 31, 2012 and Watson's Annual Report on Form 10-K for the year ended December 31, 2011. Except as expressly required by law, Watson disclaims any intent or obligation to update these forward-looking statements.

Lialda® is a registered trademark of Shire LLC.

CONTACTS: Investors:
Lisa DeFrancesco
(862) 261-7152

Media:
Charlie Mayr
(862) 261-8030

(Logo: http://photos.prnewswire.com/prnh/20100121/LA41294LOGO )

SOURCE Watson Pharmaceuticals, Inc.

share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on ACTAVIS INC
06/27 ALLERGAN : Introduces REFRESH OPTIVE® MEGA-3 Enhanced with Flaxseed Oil, Latest ..
06/23DJOne of the Last Untapped Blockbuster Diseases? Drug Companies Race to Find a ..
06/20 Novartis eye drug works with fewer injections than rival
06/20 Inhalation & Nasal Spray Generic Drugs Market - Global Trends, Market Share, ..
06/15 ALLERGAN : to Present New Data on Chronic Migraine at the American Headache Soci..
06/15 AMGEN : And Allergan Announce FDA Advisory Committee Meeting To Review ABP 215, ..
06/15 ALLERGAN : to Acquire Keller Medical, Inc., Adding Keller Funnel® to Company's L..
06/14 BIOTIME : Renevia succeeds in pivotal European facial wasting trial
06/09 ALLERGAN : to Present at the Goldman Sachs Global Healthcare Conference
06/09 ALLERGAN : to Present Data from its Anti-Infectives Portfolio at ASM Microbe 201..
More news
Sector news : Pharmaceuticals - NEC
07:55p Nestle plan hailed as only the start of Schneider's shake-up
06:52p UK blue chips led lower by Hargreaves as strong pound takes toll
06:40pDJVECTURA : In Asthma Collaboration With Novartis's Sandoz
05:33pDJGLAXOSMITHKLINE : Announces US Filing For Mepolizumab
01:10pDJMERCK AND : Today's Top Supply Chain and Logistics News From WSJ
More sector news : Pharmaceuticals - NEC